BCR-ABL Transcript Quantification Test
BCR-ABL Transcript Fusion Quantification by RT-PCR in Pune
At a glance: This molecular test measures BCR-ABL fusion transcript levels to monitor leukaemia treatment response.
The BCR-ABL transcript fusion quantification test uses real-time polymerase chain reaction (RT-PCR) to detect and quantify the abnormal BCR-ABL gene fusion. This fusion results from a chromosomal translocation (Philadelphia chromosome) and is most commonly associated with chronic myeloid leukaemia (CML) and certain acute leukaemias.
This test is primarily used for baseline assessment and ongoing treatment monitoring, helping clinicians evaluate molecular response and disease progression. At healthcare nt sickcare, the test is available through both Home Collection Facility and Direct Walk-in Facility in Pune, Maharashtra.
Test Covered
At a glance: This package includes one quantitative molecular assay.
- BCR-ABL Transcript Fusion Quantification by RT-PCR
When Is This Test Recommended?
At a glance: Recommended for diagnosis confirmation and molecular monitoring of leukaemia.
This test is advised for patients diagnosed with or suspected of having CML, or for those already on targeted therapy where regular molecular monitoring is required to assess treatment response.
Related Reading and Resources
- Educational article on leukaemia testing
- RT-PCR test preparation guide
- Compare molecular diagnostic tests
- Medical reference on BCR-ABL testing
Frequently Asked Questions
It is done at diagnosis and at regular intervals to monitor treatment response in leukaemia.
No fasting is required for the BCR-ABL RT-PCR blood test.
The test is usually performed on a peripheral blood sample.
It supports diagnosis and monitoring but must be interpreted with clinical findings.
Test Disclaimer: This test is intended for diagnostic support and treatment monitoring only. Results must be interpreted by a qualified oncologist or haematologist in clinical context. This content does not constitute medical advice. Please refer to our disclaimer policy.
Original: $6,499.00
-70%$6,499.00
$1,949.70Product Information
Product Information
Shipping & Returns
Shipping & Returns
Description
BCR-ABL Transcript Fusion Quantification by RT-PCR in Pune
At a glance: This molecular test measures BCR-ABL fusion transcript levels to monitor leukaemia treatment response.
The BCR-ABL transcript fusion quantification test uses real-time polymerase chain reaction (RT-PCR) to detect and quantify the abnormal BCR-ABL gene fusion. This fusion results from a chromosomal translocation (Philadelphia chromosome) and is most commonly associated with chronic myeloid leukaemia (CML) and certain acute leukaemias.
This test is primarily used for baseline assessment and ongoing treatment monitoring, helping clinicians evaluate molecular response and disease progression. At healthcare nt sickcare, the test is available through both Home Collection Facility and Direct Walk-in Facility in Pune, Maharashtra.
Test Covered
At a glance: This package includes one quantitative molecular assay.
- BCR-ABL Transcript Fusion Quantification by RT-PCR
When Is This Test Recommended?
At a glance: Recommended for diagnosis confirmation and molecular monitoring of leukaemia.
This test is advised for patients diagnosed with or suspected of having CML, or for those already on targeted therapy where regular molecular monitoring is required to assess treatment response.
Related Reading and Resources
- Educational article on leukaemia testing
- RT-PCR test preparation guide
- Compare molecular diagnostic tests
- Medical reference on BCR-ABL testing
Frequently Asked Questions
It is done at diagnosis and at regular intervals to monitor treatment response in leukaemia.
No fasting is required for the BCR-ABL RT-PCR blood test.
The test is usually performed on a peripheral blood sample.
It supports diagnosis and monitoring but must be interpreted with clinical findings.
Test Disclaimer: This test is intended for diagnostic support and treatment monitoring only. Results must be interpreted by a qualified oncologist or haematologist in clinical context. This content does not constitute medical advice. Please refer to our disclaimer policy.
